These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36617959)

  • 1. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.
    Yamamoto M; Sickle-Santanello B; Beard T; Essner R; Martin B; Bailey CN; Guenther JM
    Curr Med Res Opin; 2023 Mar; 39(3):417-423. PubMed ID: 36617959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating the melanoma 31-gene expression profile test with clinical and pathologic features can provide personalized precision estimates for sentinel lymph node positivity: an independent performance cohort.
    Kriza C; Martin B; Bailey CN; Bennett J
    World J Surg Oncol; 2024 Aug; 22(1):228. PubMed ID: 39215342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
    Johansson I; Tempel D; Dwarkasing JT; Rentroia-Pacheco B; Mattsson J; Ny L; Olofsson Bagge R
    Eur J Surg Oncol; 2022 Feb; 48(2):320-325. PubMed ID: 34794843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study.
    Stassen RC; Mulder EEAP; Mooyaart AL; Francken AB; van der Hage J; Aarts MJB; van der Veldt AAM; Verhoef C; Grünhagen DJ
    Eur J Surg Oncol; 2023 Dec; 49(12):107249. PubMed ID: 37907016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
    Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM
    Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.
    Kött J; Zimmermann N; Zell T; Rünger A; Heidrich I; Geidel G; Smit DJ; Hansen I; Abeck F; Schadendorf D; Eggermont A; Puig S; Hauschild A; Gebhardt C
    Eur J Cancer; 2024 May; 202():113989. PubMed ID: 38518535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.
    Gerami P; Cook RW; Russell MC; Wilkinson J; Amaria RN; Gonzalez R; Lyle S; Jackson GL; Greisinger AJ; Johnson CE; Oelschlager KM; Stone JF; Maetzold DJ; Ferris LK; Wayne JD; Cooper C; Obregon R; Delman KA; Lawson D
    J Am Acad Dermatol; 2015 May; 72(5):780-5.e3. PubMed ID: 25748297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma.
    Marchetti MA; Dusza SW; Bartlett EK
    JAMA Dermatol; 2022 Jun; 158(6):680-683. PubMed ID: 35475908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
    Scott AM; Dale PS; Conforti A; Gibbs JN
    Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction.
    Whitman ED; Koshenkov VP; Gastman BR; Lewis D; Hsueh EC; Pak H; Trezona TP; Davidson RS; McPhee M; Guenther JM; Toomey P; Smith FO; Beitsch PD; Lewis JM; Ward A; Young SE; Shah PK; Quick AP; Martin BJ; Zolochevska O; Covington KR; Monzon FA; Goldberg MS; Cook RW; Fleming MD; Hyams DM; Vetto JT
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34568719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.
    Yousaf A; Tjien-Fooh FJ; Rentroia-Pacheco B; Quattrocchi E; Kobic A; Tempel D; Kolodney M; Meves A
    Int J Dermatol; 2021 Jul; 60(7):851-856. PubMed ID: 33914348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test.
    Jarell A; Gastman BR; Dillon LD; Hsueh EC; Podlipnik S; Covington KR; Cook RW; Bailey CN; Quick AP; Martin BJ; Kurley SJ; Goldberg MS; Puig S
    J Am Acad Dermatol; 2022 Dec; 87(6):1312-1320. PubMed ID: 35810840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Integrated i31-GEP Test Outperforms the MSKCC Nomogram at Predicting SLN Status in Melanoma Patients.
    Tassavor M; Martin BJ; Glazer AM
    Anticancer Res; 2023 Oct; 43(10):4511-4516. PubMed ID: 37772588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node biopsy for melanoma: indications and rationale.
    Phan GQ; Messina JL; Sondak VK; Zager JS
    Cancer Control; 2009 Jul; 16(3):234-9. PubMed ID: 19556963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma.
    Miller JR; Lo SN; Nosrati M; Stretch JR; Spillane AJ; Saw RPM; Shannon KF; Nieweg OE; Ch'ng S; Kim KB; Leong SP; Thompson JF; Scolyer RA; Kashani-Sabet M
    JAMA Netw Open; 2023 Apr; 6(4):e236356. PubMed ID: 37074717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.
    Gannon CJ; Rousseau DL; Ross MI; Johnson MM; Lee JE; Mansfield PF; Cormier JN; Prieto VG; Gershenwald JE
    Cancer; 2006 Dec; 107(11):2647-52. PubMed ID: 17063497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compliance with sentinel lymph node biopsy guidelines for invasive melanomas treated with Mohs micrographic surgery.
    MacArthur KM; Baumann BC; Sobanko JF; Etzkorn JR; Shin TM; Higgins HW; Giordano CN; McMurray SL; Krausz A; Newman JG; Rajasekaran K; Cannady SB; Brody RM; Karakousis GC; Miura JT; Cohen JV; Amaravadi RK; Mitchell TC; Schuchter LM; Miller CJ
    Cancer; 2021 Oct; 127(19):3591-3598. PubMed ID: 34292585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma.
    Yamamoto M; Fisher KJ; Wong JY; Koscso JM; Konstantinovic MA; Govsyeyev N; Messina JL; Sarnaik AA; Cruse CW; Gonzalez RJ; Sondak VK; Zager JS
    Cancer; 2015 May; 121(10):1628-36. PubMed ID: 25677366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical sentinel lymph node biopsy for melanomas of the head and neck and upper thorax.
    Wagner JD; Park HM; Coleman JJ; Love C; Hayes JT
    Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):313-21. PubMed ID: 10722003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study.
    Koskivuo I; Talve L; Vihinen P; Mäki M; Vahlberg T; Suominen E
    Ann Surg Oncol; 2007 Dec; 14(12):3566-74. PubMed ID: 17924169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.